CNSY · Cerenome, Inc.
AI read · Good for CNSY
The AI's read
That gives Cerenome early support for repeating its treatment. But the study is small and does not prove the treatment helps patients live longer. One patient later had disease progression, and one had severe nausea. More patients and dose testing are needed before the company can set a repeat-dose plan.